DOI: 10.1055/s-00000031

Klinische Monatsblätter für Augenheilkunde

References

Ho AC, Busbee BG, Regillo CD. et al.
Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.

Ophthalmology 2014;
121: 2181-2192

Download Bibliographical Data

Search in:
Access: